Clinical trial
Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL
NCT00330252 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00330252 |
|---|---|
| Title | Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL |
| Official title | Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Genzyme, a Sanofi Company Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Chronic Lymphocytic Leukemia |
| Intervention type | Drug |
| Interventions | Rituximab, Alemtuzumab |
| Enrollment | 29 |
| Start date | May 1, 2006 |
| Primary completion | Jan 1, 2013 |
| Completion | Jan 1, 2014 |
| First posted | May 26, 2006 |
| Last update posted | May 13, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: